PDCD1LG2 and cancer: Meanwhile, Fan et al. systematically summarized the regulatory mechanisms of PD-L1 from nuclear chromatin remodeling to extracellular presentation and used Hi-C data to reveal a new TAD (chr9: 5,400,000-5,600,000) containing a super-enhancer that drives the synchronous transcription of PD-L1 and PD-L2 in high-expression cancer cells (Fan et al., 2022).